The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol—Report on the good-risk patients.
Sucha Nand
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Holly Gundacker
No relevant relationships to disclose
John E. Godwin
No relevant relationships to disclose
Cheryl L. Willman
No relevant relationships to disclose
Thomas Norwood
No relevant relationships to disclose
Harry Paul Erba
No relevant relationships to disclose
Dianna S. Howard
No relevant relationships to disclose
Steven E. Coutre
No relevant relationships to disclose
Megan Othus
No relevant relationships to disclose
Frederick R. Appelbaum
No relevant relationships to disclose